Search Results
-
Post
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
...whether this may prevent or temporarily interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings,...
-
Post
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
...with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Patients should only use Optune...
-
Post
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma
...Optune in patients entering the adjuvant treatment phase. Secondary objectives for the Optune portion of the study include assessing preliminary clinical activity of the combination of Optune, marizomib and temozolomide...
-
Post
Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
...interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Forward-Looking Statements In addition...
-
Post
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
...with your doctor whether this may prevent or temporarily interfere with Optune treatment. Please visit Optune.com/Safety for Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications,...
-
Post
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
...with your doctor whether this may prevent or temporarily interfere with Optune treatment. Please visit Optune.com/Safety for Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications,...
-
Post
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
...China.” About Optune Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to the region of the tumor. Tumor Treating Fields is a cancer therapy...
-
Post
Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma
...that demonstrated adding Optune to temozolomide extends survival while maintaining quality of life. Novocure is committed to providing access to Optune for all patients who may benefit, consistent with the...
-
Post
CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence
...or temporarily interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Forward-Looking Statements...
-
Post
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany
...with newly diagnosed GBM when Optune is added to standard chemotherapy,” said Pritesh Shah, Novocure’s Chief Commercial Officer. “In addition to Germany, Optune is broadly reimbursed in the United States,...